1.800.THE FIRM | 1.800.843.3476
The Cochran Firm Legal Blog
With Office Locations Nationwide
Monday, April 26, 2010
Protection Against Faulty Pharmaceutical Products
Pharmaceutical companies have a duty to the public: take all possible steps to ensure the safety of their products, and take action in case of any question.
Pfizer Inc. recently discontinued a phase III liver cancer study of a drug, Sutent, owing to safety issues. It was reported that patients using the medicine suffered a high incidence of serious adverse effects.
"The disappointing outcome of this trial challenges all of us to work harder to understand the complex biology of this disease," Mace Rothenburg, head of clinical development for Pfizer’s oncology unit, said in a statement.
In March, Pfizer reported disappointing results from two phase III studies of Sutent for use with advanced breast cancer. The drug is already approved for treatment of advanced kidney cancer, and had world sales of $964 million in 2009. Pfizer is testing the drug against a wide range of cancers.
Defective products of any kind are of concern to the public, and by one estimate injure more than 1 million Americans a year. However, the possible damage caused by a pharmaceutical injury is of particular concern in our age, when so many drugs are prescribed. The average citizen is hardly able to decide independently whether a drug is safe, and severe personal injury can result from a faulty drug.
At The Cochran Firm, our product liability attorneys are determined to take every step in protecting our clients. If you think that you may have sustained injury from a defective pharmaceutical product, we invite you to contact us for a free consultation at any of our nationwide offices.
Pfizer Inc. recently discontinued a phase III liver cancer study of a drug, Sutent, owing to safety issues. It was reported that patients using the medicine suffered a high incidence of serious adverse effects.
"The disappointing outcome of this trial challenges all of us to work harder to understand the complex biology of this disease," Mace Rothenburg, head of clinical development for Pfizer’s oncology unit, said in a statement.
In March, Pfizer reported disappointing results from two phase III studies of Sutent for use with advanced breast cancer. The drug is already approved for treatment of advanced kidney cancer, and had world sales of $964 million in 2009. Pfizer is testing the drug against a wide range of cancers.
Defective products of any kind are of concern to the public, and by one estimate injure more than 1 million Americans a year. However, the possible damage caused by a pharmaceutical injury is of particular concern in our age, when so many drugs are prescribed. The average citizen is hardly able to decide independently whether a drug is safe, and severe personal injury can result from a faulty drug.
At The Cochran Firm, our product liability attorneys are determined to take every step in protecting our clients. If you think that you may have sustained injury from a defective pharmaceutical product, we invite you to contact us for a free consultation at any of our nationwide offices.
Labels: main
posted by Benjamin A. Irwin at 10:53 AM
<< Home